Cited by 3,011Hepatitis C virus researchLiver Disease Diagnosis and TreatmentLiver physiology and pathology

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Natural history of liver fibrosis progression in patients with chronic hepatitis C

Poynard, Thierry, Bedossa, Pierre, Opolon, Pierre·1997·The Lancet

Open this paper in CoChat — free account

Abstract

Background Our aim was to assess the natural history of liver fibrosis progression in hepatitis C and the factors associated with this progression. Methods We recruited 2235 patients from the Observatoire de l'Hépatite C (OBSVIRC) population, the Cohorte Hépatite C Pitié-Salpétrière (DOSVIRC) population, and the original METAVIR population. All the patients had a biopsy sample compatible with chronic hepatitis C as assessed by the METAVIR scoring system (grades the stage of fibrosis on a five-point scale, F0 = no fibrosis, F4 = cirrhosis, and histological activity on a four-point scale, A0 = no activity, A3 = severe activity). No patient had received interferon treatment before the liver biopsy sample was obtained. We assessed the effect of nine factors on fibrosis progression: age at biopsy; estimated duration of infection; sex; age at infection; alcohol consumption; hepatitis C virus C (HCV) genotype; HCV viraemia; cause of infection; and histological activity grade. We defined fibrosis progression per year as the ratio between fibrosis stage in METAVIR units and the duration of infection (1 unit = one stage, 4 units = cirrhosis). Findings The median rate of fibrosis progression per year was 0.133 fibrosis unit (95% CI 0.125-0.143), which was similar to the estimates from previous studies (0.146 to 0.154). Three independent factors were associated with an increased rate of fibrosis progression: age at infection older than 40 years, daily alcohol consumption of 50 g or more, and male sex. There was no association between fibrosis progression and HCV genotype. The median estimated duration of infection for progression to cirrhosis was 30 years (28-32), ranging from 13 years in men infected after the age of 40 to 42 years in women who did not drink alcohol and were infected before the age of 40. Without treatment, 377 (33%) patients had an expected median time to cirrhosis of less than 20 years, and 356 (31%) will never progress to cirrhosis or will not progress for at least 50 years. Interpretation The host factors of ageing, alcohol consumption, and male sex have a stronger association with fibrosis progression than virological factors in HCV infection.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(96)07642-8

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bédossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,107
Self-citation
Classification of chronic hepatitis: Diagnosis, grading and staging
Desmet, V. J., Gerber, M. A., Hoofnagle, J. H., Manns, M. P., & Scheuer, P. J. (1994) · Hepatology · doi:10.1002/hep.1840190629 · Cited by 2,591
Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients With Chronic Hepatitis C
Bédossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,212
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
Kiyosawa, K., Sodeyama, T., Tanaka, E., Gibo, Y., Yoshizawa, K., Nakano, Y., Furuta, S., Akahane, Y., Nishioka, K., Purcell, R. H., et al. (1990) · Hepatology · doi:10.1002/hep.1840120409 · Cited by 1,217
Clinical Outcomes after Transfusion-Associated Hepatitis C
Tong, M. J., El-Farra, N. S., Reikes, A., & Co, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322202 · Cited by 1,191
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
Poynard, T., Leroy, V., Cohard, M., Thévenot, T., Mathurin, P., Opolon, P., & Zarski, J. (1996) · Hepatology · doi:10.1002/hep.510240405 · Cited by 671
Self-citation
The Long–Term Pathological Evolution of Chronic Hepatitis C
Yano, M., Kumada, H., Kage, M., Ikeda, K., Shimamatsu, K., INOUE, O., Hashimoto, E., Lefkowitch, J. H., Ludwig, J., & Okuda, K. (1996) · Hepatology · doi:10.1002/hep.510230607 · Cited by 597
Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis
Bisceglie, A. M. D., Goodman, Z. D., Ishak, K. G., Hoofnagle, J. H., Melpolder, J. J., & Alter, H. J. (1991) · Hepatology · doi:10.1002/hep.1840140603 · Cited by 538
Epidemiology of Hepatitis C in the West
Alter, M. J. (1995) · Seminars in Liver Disease · doi:10.1055/s-2007-1007259 · Cited by 482
A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B Hepatitis
Poynard, T., Bédossa, P., Chevallier, M., Mathurin, P., Lemonnier, C., TREPO, C. G., Couzigou, P., Payen, J. L., Sajus, M., Costa, J. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322201 · Cited by 454
Self-citation

Show all 24 references

Research works printed but not linked: 1

1995, Bilan initial. Association Francoise pour ľEtude du Foie, Lyon 1994, Gastroenterol Clin Biol, 19, 81

Sorted by citations

Items 501–600 of 1,001

Loss of c-Met accelerates development of liver fibrosis in response to CCl4 exposure through deregulation of multiple molecular pathways
Marquardt, J. U., Seo, D., Gómez-Quiroz, L. E., Uchida, K., Gillen, M. C., Kitade, M., Kaposi-Novák, P., Conner, E. A., Factor, V. M., & Thorgeirsson, S. S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.012 · Cited by 89
Double trouble: Psychiatric comorbidity and opioid addiction—All-cause and cause-specific mortality
Bogdanowicz, K., Stewart, R. J., Broadbent, M. T. M., Hatch, S. L., Hotopf, M. H., Strang, J., & Hayes, R. D. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.12.025 · Cited by 87
Efficacy and Safety of Pegylated Interferon Combined with Ribavirin for the Treatment of Older Patients with Chronic Hepatitis C
Huang, C., Yang, J., Dai, C., Huang, J., Hou, N., Hsieh, M., Lin, Z., Chen, S., Hsieh, M., Wang, L., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/650470 · Cited by 88
Improvement in Liver Pathology of Patients With β-Thalassemia Treated With Deferasirox for at Least 3 Years
Deugnier, Y., Turlin, B., Ropert, M., Cappellini, M. D., Porter, J. B., Giannone, V., Zhang, Y., Griffel, L. H., & Brissot, P. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.065 · Cited by 88
Hepatitis C in State Correctional Facilities
Spaulding, A. C., Greene, C. M., Davidson, K., Schneidermann, M., & Rich, J. D. (1999) · Preventive Medicine · doi:10.1006/pmed.1998.0418 · Cited by 89
High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities
Campbell, J. V., Hagan, H., Latka, M. H., Garfein, R. S., Golub, E. T., Coady, M. H., Thomas, D. L., & Strathdee, S. A. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.07.005 · Cited by 87
Hepatitis C virus infection: quality of life and side effects of treatment
Foster, G. R. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80411-5 · Cited by 87
Hepatitis C infection among survivors of childhood cancer
Strickland, D. K., Riely, C. A., Patrick, C. C., Jones-Wallace, D., Boyett, J. M., Waters, B., Fleckenstein, J., Dean, P. J., Davila, R., Caver, T. E., et al. (2000) · Blood · doi:10.1182/blood.v95.10.3065 · Cited by 87
Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens
Eckman, M. H., Ward, J. W., & Sherman, K. E. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.080 · Cited by 90
Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office
Yee, H. S., Chang, M. F., Pocha, C., Lim, J. K., Ross, D. B., Morgan, T. R. M., & Monto, A. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.48 · Cited by 86
Older Donor Livers Show Early Severe Histological Activity, Fibrosis, and Graft Failure After Liver Transplantation for Hepatitis C
Rayhill, S. C., Wu, Y., Katz, D. A., Voigt, M. D., LaBrecque, D. R., Kirby, P., Mitros, F. A., Kalil, R. S., Miller, R. A., Stolpen, A. H., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000270313.31328.63 · Cited by 86
Long-term efficacy of combination therapy with interferon-α2b and ribavirin for severe chronic hepatitis C in HIV-infected patients
Landau, A., Batisse, D., Piketty, C., Huyen, J. D. V., Bloch, F., Bélec, L., Bruneval, P., Weiss, L., Jian, R., & Kazatchkine, M. D. (2001) · AIDS · doi:10.1097/00002030-200111090-00010 · Cited by 86
Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals
Naggie, S., & Sulkowski, M. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.012 · Cited by 85
Higher serum testosterone is associated with increased risk of advanced hepatitis C–related liver disease in males
White, D. L., Tavakoli-Tabasi, S., Kuzniarek, J., Pascua, R., Ramsey, D. J., & El‐Serag, H. B. (2011) · Hepatology · doi:10.1002/hep.24618 · Cited by 85
Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis
Iizuka, N., Oka, M., Yamada‐Okabe, H., Mori, N., Tamesa, T., Okada, T., Takemoto, N., 橋本, 毅., Tangoku, A., Hamada, K., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206401 · Cited by 85
Adipokines in Liver Cirrhosis
Buechler, C., Haberl, E. M., Rein‐Fischboeck, L., & Aslanidis, C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071392 · Cited by 87
Results of Retransplantation for Recurrent Hepatitis C
Roayaie, S., Schiano, T. D., Thung, S. N., Emre, S., Fishbein, T., Miller, C. M., & Schwartz, M. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.010 · Cited by 84
Immunopathogenesis of hepatitis C virus infection
Freeman, A. J., Marinos, G., Ffrench, R. A., & Lloyd, A. R. (2001) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.2001.01036.x · Cited by 85
Alcohol Consumption, Folate Intake, Hepatocellular Carcinoma, and Liver Disease Mortality
Persson, E. C., Schwartz, L. M., Park, Y., Trabert, B. L., Hollenbeck, A. R., Graubard, B. I., Freedman, N. D., & McGlynn, K. A. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-1169 · Cited by 84
An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads
Sezaki, H., Suzuki, F., Akuta, N., Yatsuji, H., Hosaka, T., Kobayashi, M., Suzuki, Y., Arase, Y., Ikeda, K., Miyakawa, Y., et al. (2009) · Intervirology · doi:10.1159/000213504 · Cited by 82
Dual cut‐off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation
Viganò, M., Paggi, S., Lampertico, P., Fraquelli, M., Massironi, S., Ronchi, G., Rigamonti, C., Conte, D., & Colombo, M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04722.x · Cited by 83
Transforming growth factor-β1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection
Wang, H. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i13.1929 · Cited by 83
Treatment of hepatitis C
Kim, A. I., & Saab, S. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.01.073 · Cited by 83
What are ‘true normal’ liver stiffness values using FibroScan®?: a prospective study in healthy living liver and kidney donors in South Korea
Kim, S. U., Choi, G. H., Han, W. K., Kim, B. K., Park, J. Y., Kim, D. Y., Choi, J. S., Yang, S. C., Choi, E. H., Ahn, S. H., et al. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02172.x · Cited by 85
Factors contributing to ribavirin‐induced anemia
Nomura, H., Tanimoto, H., Kajiwara, E., Shimono, J., Maruyama, T., Yamashita, N., Nagano, M., Higashi, M., Mukai, T., Matsui, Y., et al. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03459.x · Cited by 82
Human DDX3Y, the Y-encoded isoform of RNA helicase DDX3, rescues a hamster temperature-sensitive ET24 mutant cell line with a DDX3X mutation
Sekiguchi, T., Iida, H., Fukumura, J., & Nishimoto, T. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.07.005 · Cited by 82
Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population
Piasecki, B. A., Lewis, J. D., Reddy, K. R., Bellamy, S. L., Porter, S. B., Weinrieb, R. M., Stieritz, D. D., & Chang, K. (2004) · Hepatology · doi:10.1002/hep.1840400419 · Cited by 82
Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance
Oleksyk, T. K., Thio, C. L., Truelove, A. L., Goedert, J. J., Donfield, S. M., Kirk, G. D., Thomas, D. L., O’Brien, S. J., & Smith, M. W. (2005) · Genes and Immunity · doi:10.1038/sj.gene.6364188 · Cited by 82
The severity of liver fibrosis is associated with high leptin levels in chronic Hepatitis C
Piche, T., Burel‐Vandenbos, F., Abakar-Mahamat, A., Vanbiervliet, G., Barjoan, E. M., Calle, G., Giudicelli, J., Ferruà, B., Laffont, C., Benzaken, S., et al. (2004) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00483.x · Cited by 82
Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients
Motawi, T. K., Shaker, O. G., El‐Maraghy, S. A., & Senousy, M. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137706 · Cited by 80
Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model
Perlemuter, G., Lettéron, P., Carnot, F., Zavala, F., Pessayre, D., Nalpas, B., & Bréchot, C. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00414-8 · Cited by 81
Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study
Hagström, H., Stal, P. I., Hultcrantz, R. W., Hemmingsson, T., & Andréasson, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.019 · Cited by 86
Feminization of Male Mouse Liver by Persistent Growth Hormone Stimulation: Activation of Sex-Biased Transcriptional Networks and Dynamic Changes in Chromatin States
Lau-Corona, D., Suvorov, A., & Waxman, D. J. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00301-17 · Cited by 73
A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase
Okanoue, T., Makiyama, A., Nakayama, M., Sumida, Y., Mitsuyoshi, H., Nakajima, T., Yasui, K., Minami, M., & Itoh, Y. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.04.008 · Cited by 80
Parenchymal Extinction: Coagulation and Hepatic Fibrogenesis
Anstee, Q. M., Wright, M., Goldin, R. D., & Thursz, M. R. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.09.013 · Cited by 80
Rate of natural disease progression in patients with chronic hepatitis C
Zarski, J., Hutchison, J. M., Zarski, J., Stürm, N., Garcia‐Kennedy, R., Hodaj, E., Truta, B., Wright, T. L., & Gish, R. G. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00387-2 · Cited by 80
Environmental factors as disease accelerators during chronic hepatitis C
Mallat, A., Hézode, C., & Lotersztajn, S. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.004 · Cited by 78
Risk factors for liver fibrosis progression in patients with chronic hepatitis C
de Torres, M., & Poynard, T. (2003) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32152-0 · Cited by 80
Self-citation
Diabetes Mellitus May Be Associated with Hepatocarcinogenesis in Patients with Chronic Hepatitis C
Tazawa, J., Maeda, M., Nakagawa, M., Ohbayashi, H., Kusano, F., Yamane, M., Sakai, Y., & Suzuki, K. (2002) · Digestive Diseases and Sciences · doi:10.1023/a:1014715327729 · Cited by 79
Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C
Viana, M. S. V. B., Takei, K., Yamaguti, D. C. C., Guz, B., & Strauss, E. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31807-1 · Cited by 79
Do Type and Duration of Antiretroviral Therapy Attenuate Liver Fibrosis in HIV--Hepatitis C Virus--Coinfected Patients?
Verma, S., Wang, C., Govindarajan, S., Kanel, G. C., Squires, K., & Bonacini, M. (2005) · Clinical Infectious Diseases · doi:10.1086/499055 · Cited by 79
Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis c
Wong, J. B., Poynard, T., Ling, M.-H., Albrecht, J. K., Pauker, S. G., & on behalf of the International Hepatitis Interventional Therapy (IHIT) Group (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02089.x · Cited by 79
Self-citation
Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b
Kawaoka, T., Hayes, C. N., Ohishi, W., Ochi, H., MAEKAWA, T., Abe, H., Tsuge, M., Mitsui, F., Hiraga, N., Imamura, M., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.032 · Cited by 78
Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection
Mendeni, M., Focà, E., Gotti, D., Ladisa, N., Angarano, G., Albini, L., Castelnuovo, F., Carosi, G., Quirós-Roldán, E., & Torti, C. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir071 · Cited by 78
Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings
Assoumou, S. A., Tasillo, A., Leff, J. A., Schackman, B. R., Drainoni, M., Horsburgh, C. R., Barry, M. A., Regis, C., Kim, A. Y., Marshall, A. D., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix798 · Cited by 78
Role of Ultrasound Methods for the Assessment of NAFLD
Petzold, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154581 · Cited by 78
Adipose-Derived Stem Cells Can Abrogate Chemical-Induced Liver Fibrosis and Facilitate Recovery of Liver Function
Harn, H., Lin, S., Hung, S.-H., Subeq, Y., Li, Y.-S., Syu, W., Ding, D., Lee, R.-P., Hsieh, D.-K., Lin, P., et al. (2012) · Cell Transplantation · doi:10.3727/096368912x652959 · Cited by 77
Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial
Fontana, R. J., Bieliauskas, L. A., Back‐Madruga, C., Lindsay, K. L., Kronfol, Z., Lok, A. S.-F., Padmanabhan, L., & the HALT-C Trial Group (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.04.006 · Cited by 78
Hepatitis C in the General Adult Population of Oslo: Prevalence and Clinical Spectrum
Dalgård, O., Jeansson, S. L., Skaug, K., Raknerud, N., & Bell, H. (2003) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520310004542 · Cited by 78
Longitudinal Analysis of Hepatitis C Virus Replication and Liver Fibrosis Progression in Renal Transplant Recipients
Izopet, J., Rostaing, L. P. E., Sauné, K., Cisterne, J., Pasquier, C., Rumeau, J., Duffaut, M., Durand, D., & Puel, J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315355 · Cited by 78
Hepatic resection for hepatocellular carcinoma in the elderly
Kaibori, M., Matsui, K., Ishizaki, M., Saito, T., Kitade, H., Matsui, Y., & Kwon, A. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21221 · Cited by 78
The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre
Datz, C., Cramp, M., Haas, T., Dietze, O., Nitschko, H., Froesner, G., Muss, N., Sandhofer, F., & Vogel, W. (1999) · Gut · doi:10.1136/gut.44.4.563 · Cited by 79
ALCOHOL-INDUCED LIVER DISEASE
Maddrey, W. C. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70099-4 · Cited by 78
Replication of the hepatitis C virus in cell culture
Bartenschlager, R. F. W., KAUL, A., & Sparacio, S. (2003) · Antiviral Research · doi:10.1016/j.antiviral.2003.08.016 · Cited by 78
Estimation of Early Hepatitis C Viral Clearance in Patients Receiving Daily Interferon and Ribavirin Therapy Using A Mathematical Model
Bekkering, F. C., Stalgis, C., McHutchison, J. G., Brouwer, J. T., & Perelson, A. S. (2001) · Hepatology · doi:10.1053/jhep.2001.21552 · Cited by 78
Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B
Viganò, M., Valenti, L. V. C., Lampertico, P., Facchetti, F., Motta, B. M., D’Ambrosio, R., Romagnoli, S., Dongiovanni, P., Donati, B., Fargion, S. R., et al. (2013) · Hepatology · doi:10.1002/hep.26445 · Cited by 77
Liver fibrosis increases the risk of intrahepatic recurrence after hepatectomy for hepatocellular carcinoma
Ko, S., Kanehiro, H., Hisanaga, M., Nagao, M., Ikeda, N., & Nakajima, Y. (2002) · British journal of surgery · doi:10.1046/j.0007-1323.2001.01969.x · Cited by 77
HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations
Backus, L. I., Boothroyd, D. B., & Deyton, L. (2005) · AIDS · doi:10.1097/01.aids.0000192065.09281.01 · Cited by 78
Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community‐based register study
Duberg, A., Törner, A., Davíðsdóttir, L. G., Aleman, S., Blaxhult, A., Svensson, Å., Hultcrantz, R. W., Bäck, E., & Ekdahl, K. (2008) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2008.00982.x · Cited by 77
Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience
Idrees, M., Rafique, S., Rehman, I.-U., Akbar, H., Yousaf, M. Z., Butt, S., Awan, Z., Manzoor, S., Akram, M., Aftab, M., et al. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5080 · Cited by 77
LIVER DISEASE IN THE ELDERLY
Regev, A., & Schiff, E. R. (2001) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(05)70195-3 · Cited by 77
Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus
Chekuri, S., Nickerson, J. E., Bichoupan, K., Sefcik, R. K., Doobay, K., Chang, S., Delbello, D., Harty, A., Dieterich, D. T., Perumalswami, P., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159413 · Cited by 77
Progression of fibrosis in untreated patients with hepatitis C virus infection
Lagging, M., Westin, J., Svensson, E., Aires, N., Dhillon, A. P., Lindh, M., Wejstål, R., & Norkrans, G. (2002) · Liver International · doi:10.1034/j.1600-0676.2002.01623.x · Cited by 77
Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis
Su, T., Kao, J., & Liu, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150610578 · Cited by 78
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population
Poynard, T., Munteanu, M., Deckmyn, O., Ngo, Y., Drane, F., Castille, J. M., Housset, C., Ratziu, V., & Imbert‐Bismut, F. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.04.025 · Cited by 76
Self-citation
Role of Interleukin 28B rs12979860 C/T Polymorphism on the Histological Outcome of Chronic Hepatitis C: Relationship with Gender and Viral Genotype
Falleti, E., Bitetto, D., Fabris, C., Cussigh, A., Fornasiere, E., Cmet, S., Fumolo, E., Bignulin, S., Fontanini, E., Cerutti, A., et al. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9547-1 · Cited by 76
Host Genetic Factors and Antiviral Immune Responses to Hepatitis C Virus
Thio, C. L. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.03.002 · Cited by 76
Alcohol Use and HIV Pharmacotherapy
Kresina, T. F., Flexner, C. W., Sinclair, J. F., Correia, M. A., Stapleton, J. T., Adeniyi‐Jones, S., Cargill, V. A., & Cheever, L. W. (2002) · AIDS Research and Human Retroviruses · doi:10.1089/08892220260139495 · Cited by 75
Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection†
Perumalswami, P., Kleiner, D. E., Lutchman, G. A., Heller, T., Borg, B. B., Park, Y., Liang, T. J., Hoofnagle, J. H., & Ghany, M. G. (2006) · Hepatology · doi:10.1002/hep.21078 · Cited by 76
Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection
Hu, K., Vierling, J. M., & Redeker, A. G. (2001) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2001.00253.x · Cited by 76
Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis c
Wong, J. B. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)00881-9 · Cited by 76
Importance of Patient, Provider, and Facility Predictors of Hepatitis C Virus Treatment in Veterans: A National Study
Kramer, J. R., Kanwal, F., Richardson, P. A., Giordano, T. P., Petersen, L. A., & El‐Serag, H. B. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.430 · Cited by 75
KASL clinical practice guidelines: management of hepatitis C
(2016) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2016.22.1.76 · Cited by 76
Role of Estrogen in Liver Cancer
Villa, E. (2008) · Women s Health · doi:10.2217/17455057.4.1.41 · Cited by 75
Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C
Verveer, C., Zondervan, P. E., ten Kate, F. J. W., Hansen, B. E., Janssen, H. L. A., & de Knegt, R. J. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02663.x · Cited by 75
Hepatitis C virus infection and liver steatosis
Ramalho, F. J. (2003) · Antiviral Research · doi:10.1016/j.antiviral.2003.08.007 · Cited by 75
The Role of Autophagy and NLRP3 Inflammasome in Liver Fibrosis
Tao, Y., Wang, N., Qiu, T., & Sun, X. (2020) · BioMed Research International · doi:10.1155/2020/7269150 · Cited by 74
Antibody Production and In Vitro Behavior of CD27-Defined B-Cell Subsets: Persistent Hepatitis C Virus Infection Changes the Rules
Racanelli, V., Frassanito, M. A., Leone, P., Galiano, M., Re, V. D., Silvestris, F., & Dammacco, F. (2006) · Journal of Virology · doi:10.1128/jvi.80.8.3923-3934.2006 · Cited by 74
Association of Hepatitis C Virus With Alcohol Use Among U.S. Adults: NHANES 2003–2010
Taylor, A. L., Denniston, M. M., Klevens, R. M., McKnight-Eily, L. R., & Jiles, R. B. (2016) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2016.02.033 · Cited by 74
Hepatitis C viral infection in the immunosuppressed patient
Collier, J. D., & Heathcote, J. (1998) · Hepatology · doi:10.1002/hep.510270102 · Cited by 74
Metabolic Reprogramming of Liver Fibrosis
Delgado, M. E., Cárdenas, B., Farran, N., & Fernández, M. (2021) · Cells · doi:10.3390/cells10123604 · Cited by 75
Ribavirin plus interferon versus interferon for chronic hepatitis C
Brok, J. S., Gluud, L. L., & Gluud, C. N. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005445.pub2 · Cited by 73
Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C
Guyader, D., de Lajarte‐Thirouard, A., Erdtmann, L., Rakba, N., Jacquelinet, S., Danielou, H., Perrin, M., Jouanolle, A., Brissot, P., & Deugnier, Y. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.09.021 · Cited by 73
Hepatitis C virus co‐infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus‐positive patients
Piroth, Grappin, Cuzin, Mouton, Bouchard, Raffi, Rey, Peyramond, Gourdon, Drobacheff, et al. (2000) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2000.00227.x · Cited by 73
Prediction of microvascular invasion of hepatocellular carcinoma by pre-operative CT imaging
Chou, C.-T., Chen, R.-C., Lee, C.-W., Ko, C.-J., Wu, H.-K., & Chen, Y.-L. (2012) · British Journal of Radiology · doi:10.1259/bjr/65897774 · Cited by 73
Sustained telomere length in hepatocytes and cholangiocytes with increasing age in normal liver
Verma, S., Tachtatzis, P., Penrhyn-Lowe, S., Scarpini, C. G., Jurk, D., von Zglinicki, T., Coleman, N., & Alexander, G. (2012) · Hepatology · doi:10.1002/hep.25787 · Cited by 73
Mitochondrial Dysfunction in Hepatitis C
Korenaga, M., Okuda, M., Otani, K., Wang, T., Li, Y., & Weinman, S. A. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000155517.02468.46 · Cited by 73
Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: A case-control study
Allory, Y., Charlotte, F., Benhamou, Y., Opolon, P., Charpentier, Y. L., & Poynard, T. (2000) · Human Pathology · doi:10.1016/s0046-8177(00)80201-4 · Cited by 73
Self-citation
Severity and correlates of liver disease in hepatitis C virus-infected injection drug users
Rai, R., Wilson, L. E., Astemborski, J. A., Anania, F. A., Torbenson, M. S., Spoler, C., Vlahov, D., Strathdee, S. A., Boitnott, J., Nelson, K. E., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.33151 · Cited by 73
HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension
Reiberger, T., Ferlitsch, A., Sieghart, W., Kreil, A., Breitenecker, F., Rieger, A., Schmied, B., Gangl, A., & Peck‐Radosavljevic, M. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2009.01197.x · Cited by 72
Fibrosis progression in initially mild chronic hepatitis C
Boccato, S., Pistis, R., Noventa, F., Guido, M., Benvegnù, L., & Alberti, A. (2005) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2005.00683.x · Cited by 72
Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients
Rumi, M. G., Filippi, F. D., Vecchia, C. L., Donato, M. F., Gallus, S., Ninno, E. D., & Colombo, M. (2005) · Gut · doi:10.1136/gut.2004.048009 · Cited by 72
A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users
Mehta, S. H., Thomas, D. L., Sulkowski, M., Safaein, M., Vlahov, D., & Strathdee, S. A. (2005) · AIDS · doi:10.1097/01.aids.0000192088.72055.90 · Cited by 71
Natural history of chronic hepatitis C virus infection
Ascione, A., Tartaglione, M. T., & Costanzo, G. G. D. (2007) · Digestive and Liver Disease · doi:10.1016/s1590-8658(07)80003-x · Cited by 74
The Multifaceted Roles of Autophagy in Flavivirus-Host Interactions
Ke, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123940 · Cited by 78
Spectrum of Disease in U.S. Veteran Patients With Hepatitis C
Nguyen, H. A., Miller, A. I., Dieperink, E. W., Willenbring, M. L., Tetrick, L. L., Durfee, J. M., Ewing, S. L., & Ho, S. B. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05800.x · Cited by 72
Hepatitis C and alcohol
Degos, F. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80386-9 · Cited by 72
Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response
Tachi, Y., Hirai, T., Miyata, A., Ohara, K., Iida, T., Ishizu, Y., Honda, T., Kuzuya, T., Hayashi, K., Ishigami, M., et al. (2014) · Hepatology Research · doi:10.1111/hepr.12331 · Cited by 71
Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C
Sullivan, S. D., Craxı̀, A., Alberti, A., Giuliani, G., Carli, C. D., Wintfeld, N., Patel, K., & Green, J. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422040-00004 · Cited by 71
Liver Cancer
London, W. T., & McGlynn, K. A. (2006) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195149616.003.0039 · Cited by 71

Authors: Poynard, T., Bedossa, P., & Opolon, P.
Affiliations: Centre National de la Recherche Scientifique (FR)
Corresponding author: Poynard, Thierry
ORCID: Poynard, Thierry
Venue: The Lancet
Publisher: Elsevier BV
Published: 1997-03
Volume: 349
Issue: 9055
Pages: 825-832
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(96)07642-8
OpenAlex: W2132290252
Cited by: 3,011
References: 24
Citations by year: 2026: 16 · 2025: 35 · 2024: 33 · 2023: 38 · 2022: 43 · 2021: 45 · 2020: 71 · 2019: 74 · 2018: 72 · 2017: 90 · 2016: 117 · 2015: 141 · 2014: 120 · 2013: 138 · 2012: 114
FWCI: 60.07
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Funders: Association pour la Recherche sur le Cancer
Assistance Publique - Hôpitaux de Paris
Assistance publique-Hôpitaux de Paris
Topics: Health Sciences › Medicine › Hepatology › Hepatitis C virus research
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: chronic hepatitis C, liver fibrosis progression, natural history (disease), METAVIR scoring, liver cirrhosis, age at infection, alcohol consumption, sex differences, HCV genotypes, HCV viraemia, host factors, infection duration, histological activity, liver biopsy
MeSH terms: Adult, Age Factors, Alcohol Drinking, Biopsy, Cross-Sectional Studies, Female, Hepatitis, Chronic, Hepatitis C, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Risk Factors, Sex Factors, Time Factors, Prevalence, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Natural history of liver fibrosis progression in patients with chronic hepatitis C

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks